Transition to AIM Specialty Health Perirectal Hydrogel Spacer for Prostate Radiotherapy Clinical Appropriateness Guideline

Effective November 6, 2022, Anthem Blue Cross and Blue Shield will transition the Clinical Criteria for medical necessity review of perirectal hydrogel spacer to the AIM Specialty Health_®* (AIM) Perirectal Hydrogel Spacer for Prostate Radiotherapy Clinical Appropriateness Guideline.

 

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

• Access AIM’s ProviderPortal_SM directly at https://providerportal.com. Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
• Access AIM via Availity* at availity.com.

 

For questions related to guidelines, contact AIM via email at aim.guidelines@aimspecialtyhealth.com.

 

Additionally, you may access and download a copy of the current and upcoming guidelines here.

 

* AIM Specialty Health is an independent company providing some utilization review services on behalf of Anthem Blue Cross and Blue Shield.
* Availity, LLC is an independent company providing administrative support services on behalf of Anthem Blue Cross and Blue Shield.

NVBCBS-CM-006042-22-CPN5953